{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:37:40Z","timestamp":1791401860801,"version":"4.3.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi & Co, Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cefiderocol is the first antibiotic with effluent flow rate\u2013based dosing recommendations outlined in the product label for patients receiving continuous renal replacement therapy (CRRT). We aimed to investigate the population pharmacokinetics of cefiderocol among patients receiving CRRT and validate these dosing recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter, prospective cefiderocol pharmacokinetic study among intensive care unit patients receiving CRRT was conducted (2022\u20132023). Blood sampling was performed at steady-state and cefiderocol concentrations were assayed by validated liquid chromatography\u2013tandem mass spectrometry. Population pharmacokinetic analyses were conducted in Pmetrics using R software. The free time above the minimum inhibitory concentration (f T &amp;gt; MIC) and total daily area under the concentration time curve (AUCdaily) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen patients with effluent flow rates ranging from 2.1 to 5.1 L\/h were enrolled. Cefiderocol concentrations best fitted a 2-compartment model. Mean \u00b1 standard deviation (SD) parameter estimates for clearance, central compartment volume, and intercompartment transfer constants (k12 and k21) were 3.5 \u00b1 1.5 L\/hour, 10.7 \u00b1 8.4 L, 3.9 \u00b1 1.8\u2005hours\u22121, and 2.2 \u00b1 2.2\u2005hours\u22121, respectively. With simulations based on product label dosing recommendations, all patients achieved 100% fT &amp;gt; MIC up to MIC 8\u2005mg\/L with an AUCdaily (mean \u00b1 SD) of 1444 \u00b1 423\u2005mg \u00d7 hour\/L. Cefiderocol was well tolerated among the 14 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current package insert dosing recommendations resulted in pharmacodynamically optimized cefiderocol exposures. Cefiderocol concentrations exceeded relevant MIC breakpoints in all patients at each effluent flow rate, and AUCdaily was within the range observed in patients in the phase 3 clinical trials, suggestive of a safe and therapeutic drug profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae451","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:03:05Z","timestamp":1722880985000},"source":"Crossref","is-referenced-by-count":12,"title":["Validation of Cefiderocol Package Insert Dosing Recommendation for Patients Receiving Continuous Renal Replacement Therapy: A Prospective Multicenter Pharmacokinetic Study"],"prefix":"10.1093","volume":"11","author":[{"given":"Aliaa","family":"Fouad","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Kobic","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banner\u2013University Medical Center , Phoenix, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson P","family":"Nicolasora","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Banner\u2013University Medical Center , Phoenix, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L Thompson","family":"Bastin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Kentucky Medical Center , Lexington, Kentucky ,","place":["USA"]},{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy , Lexington, Kentucky ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Adams","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky College of Medicine , Lexington, Kentucky ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Fratoni","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ye","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]},{"name":"Division of Infectious Diseases, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-0924","authenticated-orcid":false,"given":"Tomefa E","family":"Asempa","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2024102921291019500_ofae451-B1","first-page":"479730","article-title":"Epidemiology of acute kidney injury in the intensive care unit","volume":"2013","author":"Case","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"2024102921291019500_ofae451-B2","doi-asserted-by":"crossref","first-page":"4278579","DOI":"10.1155\/2016\/4278579","article-title":"Hospital mortality in the United States following acute kidney injury","volume":"2016","author":"Brown","year":"2016","journal-title":"Biomed Res Int"},{"key":"2024102921291019500_ofae451-B3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","article-title":"Acute kidney injury","volume":"394","author":"Ronco","year":"2019","journal-title":"Lancet"},{"key":"2024102921291019500_ofae451-B4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13613-020-0648-y","article-title":"Prescription of CRRT: a pathway to optimize therapy","volume":"10","author":"Karkar","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2024102921291019500_ofae451-B5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","article-title":"Palevsky PM: continuous renal replacement therapy: who, when, why, and how","volume":"155","author":"Tandukar","year":"2019","journal-title":"Chest"},{"key":"2024102921291019500_ofae451-B6","first-page":"760","article-title":"Acute renal replacement in the intensive care unit: now and tomorrow","volume":"3","author":"Bellomo","year":"1995","journal-title":"New Horiz"},{"key":"2024102921291019500_ofae451-B7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/444500","article-title":"Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy","volume":"41","author":"Trotman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2024102921291019500_ofae451-B8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2024102921291019500_ofae451-B9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/MCC.0b013e3282f0a3d3","article-title":"Drug dosing in continuous renal replacement therapy: general rules","volume":"13","author":"Schetz","year":"2007","journal-title":"Curr Opin Crit Care"},{"key":"2024102921291019500_ofae451-B10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-26202-4_5","volume-title":"Pediatric continuous renal replacement therapy: principles and practice","author":"Assadi","year":"2016"},{"key":"2024102921291019500_ofae451-B11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"2024102921291019500_ofae451-B12","author":"Shionogi Inc","year":"2021"},{"key":"2024102921291019500_ofae451-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann Intensive Care"},{"key":"2024102921291019500_ofae451-B14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024102921291019500_ofae451-B15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102921291019500_ofae451-B16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024102921291019500_ofae451-B17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12882-021-02248-7","article-title":"Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy","volume":"22","author":"Andrews","year":"2021","journal-title":"BMC Nephrol"},{"key":"2024102921291019500_ofae451-B18","doi-asserted-by":"crossref","first-page":"e02031-18","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102921291019500_ofae451-B19","article-title":"AST news update June 2023: the latest on testing cefiderocol","author":"Clinical and Laboratory Standards Institute","year":"2023"},{"key":"2024102921291019500_ofae451-B20","doi-asserted-by":"crossref","first-page":"e01437-20","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102921291019500_ofae451-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","article-title":"The clinical relevance of plasma protein binding changes","volume":"52","author":"Roberts","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2024102921291019500_ofae451-B22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1034\/j.1399-6576.2001.450802.x","article-title":"Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients","volume":"45","author":"Bugge","year":"2001","journal-title":"Acta Anaesthesiol Scand"},{"key":"2024102921291019500_ofae451-B23","doi-asserted-by":"crossref","first-page":"e01391-17","DOI":"10.1128\/AAC.01391-17","article-title":"Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis","volume":"62","author":"Kawaguchi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102921291019500_ofae451-B24","doi-asserted-by":"crossref","first-page":"e01381-16","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function","volume":"61","author":"Katsube","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102921291019500_ofae451-B25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/cpt.2703","article-title":"Cefiderocol dosing for patients receiving continuous renal replacement therapy","volume":"112","author":"Wei","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2024102921291019500_ofae451-B26","doi-asserted-by":"crossref","first-page":"ofab252","DOI":"10.1093\/ofid\/ofab252","article-title":"Cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration","volume":"8","author":"Kobic","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024102921291019500_ofae451-B27","doi-asserted-by":"crossref","first-page":"106395","DOI":"10.1016\/j.ijantimicag.2021.106395","article-title":"Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration","volume":"58","author":"Fratoni","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024102921291019500_ofae451-B28","doi-asserted-by":"crossref","first-page":"ofac484","DOI":"10.1093\/ofid\/ofac484","article-title":"Pharmacokinetic analysis and in vitro synergy evaluation of cefiderocol, sulbactam, and tigecycline in an extensively drug-resistant Acinetobacter baumannii pneumonia patient receiving continuous venovenous hemodiafiltration","volume":"9","author":"Kobic","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024102921291019500_ofae451-B29","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/bcp.15901","article-title":"Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration","volume":"89","author":"M\u00f6hlmann","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2024102921291019500_ofae451-B30","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3390\/antibiotics11121830","article-title":"Pharmacokinetic of cefiderocol in critically ill patients receiving renal replacement therapy: a case series","volume":"11","author":"Mornese Pinna","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024102921291019500_ofae451-B31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024102921291019500_ofae451-B32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024102921291019500_ofae451-B33","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024102921291019500_ofae451-B34","doi-asserted-by":"crossref","first-page":"e1065","DOI":"10.1097\/CCE.0000000000001065","article-title":"A new dosing frontier: retrospective assessment of effluent flow rates and residual renal function among critically ill patients receiving continuous renal replacement therapy","volume":"6","author":"Lakshmipathy","year":"2024","journal-title":"Crit Care Explor"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/10\/ofae451\/60198432\/ofae451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/10\/ofae451\/60198432\/ofae451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T17:29:28Z","timestamp":1730222968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae451\/7801614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae451","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,27]]},"article-number":"ofae451"}}